• Diphenyleneiodonium chloride Workflow Guide

  2026-09-21

  Diphenyleneiodonium chloride enables side-by-side interrogation of oxidase-linked ROS and GPR3-associated cAMP responses, but its broad target profile demands careful controls. This workflow translates a recent citrus canker study into practical redox, ferroptosis-oriented, and cell-signaling assay strategies.

• Repaglinide and the Energy–DNA Repair Axis

  2026-09-21

  Energy deficiency can reshape DNA repair through ATG4B nuclear translocation and disruption of PRMT1-dependent MRE11 regulation in acute myeloid leukemia. This article positions Repaglinide as a carefully bounded metabolic-context perturbation for translational studies—not as a validated ATG4B inhibitor or leukemia treatment—and outlines how to build a rigorous workflow around that distinction.

• Isoproterenol Sulfate Dihydrate in SAN Research

  2026-09-20

  Isoproterenol sulfate dihydrate provides a controllable acute stimulus for beta-adrenergic receptor signaling in human SAN-plexus assembloids. Used alongside electrophysiology, calcium imaging, and neural co-culture comparisons, it helps distinguish intrinsic pacemaker maturation from reversible sympathetic-like modulation.

• AG-120 and the Metabolic Logic of IDH1 AML

  2026-09-19

  AG-120 (Ivosidenib) translates mutant IDH1 biology into a measurable differentiation strategy for AML research. By connecting 2-hydroxyglutarate reduction with CD44-mediated metabolic rewiring, this article outlines how translational teams can design stronger pharmacodynamic, resistance, and combination studies.

• From Interaction Maps to Translational Decisions

  2026-09-18

  Protein interaction data become valuable when they change a biological or development decision. This thought-leadership article connects the genomic and field findings from a recent Trichoderma–peanut study with practical strategies for validating candidate protein partners. It explains how Fc capture, magnetic separation, controls, elution choices, and orthogonal confirmation can turn a co-IP experiment into a defensible evidence chain. The Protein A/G Magnetic Co-IP/IP Kit is presented not as a substitute for experimental design, but as a standardized capture layer for moving from candidate discovery to mechanistic confidence.

• (R)-MG132 for Causal Proteasome Assays

  2026-09-18

  (R)-MG132 is an inactive MG-132 enantiomer for separating proteasome-dependent effects from solvent, cytotoxic, and off-target responses. This article presents a causal assay framework linking stereochemical controls to HNRNPU lactylation and serine-metabolism studies.

• Tamoxifen Workflows for Cancer and CreER Research

  2026-09-17

  Tamoxifen supports both established estrogen-receptor studies and newer immune-oncology workflows that pair macrophage reprogramming with radiotherapy. This guide translates those use cases into practical preparation, assay-design, CreER controls, and troubleshooting strategies.

• Chloroquine Diphosphate in Ferroptosis Assays

  2026-09-17

  Chloroquine Diphosphate can function as an orthogonal autophagy and lysosomal perturbation tool in AML ferroptosis research. This article translates ACSL4–DGLA findings into assay design, interpretation, and controls without confusing autophagy modulation with proof of ferroptotic death.

• Ether Lipids Shape B Cell Antibody Responses

  2026-09-16

  This reference study establishes a causal link between B-cell-intrinsic ether lipid biosynthesis and the magnitude, affinity maturation, and germinal-center development of antibody responses. By combining inducible Dhrs7b loss-of-function models with imaging mass spectrometry, immunization, and cellular assays, it identifies PexRAP-dependent control of oxidative stress and membrane peroxidation as a mechanism supporting B-cell survival.

• Hoechst 33342/PI Double Staining Kit Guide

  2026-09-16

  The Hoechst 33342/PI Double Staining Kit (K2237) provides a two-color microscopy workflow for comparing nuclear chromatin changes with loss of membrane integrity in cell death studies. It is intended for scientific research, not diagnostic or medical use, and should be interpreted with appropriate controls rather than as a standalone classification method.

• Anlotinib Hydrochloride: Anti-Angiogenic TKI

  2026-09-15

  Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor with potent anti-angiogenic activity centered on VEGFR2, PDGFRβ, and FGFR1. Preclinical evidence supports its use in endothelial migration, capillary tube formation, receptor-phosphorylation, and cancer research workflows, while remaining distinct from clinical efficacy evidence.

• MDM1, p53, and Chemoradiotherapy Sensitivity in CRC

  2026-09-15

  A 2025 Cancer Biology & Medicine study identifies MDM1 as a functional regulator and potential biomarker of chemoradiotherapy response in colorectal cancer. Its experiments connect MDM1 overexpression with reduced YBX1 occupancy at the TP53 promoter, increased p53 expression, and enhanced apoptosis, providing a mechanistic framework for therapy sensitivity and resistance.

• Separating Growth Arrest from Cancer Cell Death

  2026-09-14

  Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central contribution is a framework for distinguishing growth inhibition from cell killing while accounting for differences in response magnitude and timing.

• JXY, TLR4, and M1 Macrophages in CAC

  2026-09-14

  The reference study shows that Jiedu Xiaozheng Yin suppresses colitis-associated colorectal cancer in mice while shifting intestinal macrophages toward an M1-like phenotype through TLR4-associated signaling. Its integrated in vivo, cell-based, and pharmacological-antagonist design provides a useful framework for connecting immune polarization with tumor progression, while leaving the direct molecular targets and clinical relevance unresolved.

• Nicotinamide Riboside Chloride in Translational Models

  2026-09-13

  Nicotinamide Riboside Chloride (NIAGEN) offers a practical way to investigate NAD+ biology across metabolic dysfunction research and neurodegenerative disease models. This article connects its mechanistic rationale with reproducible iPSC-derived retinal ganglion cell workflows, while distinguishing established evidence from testable translational hypotheses.

8594 records 1/573 page Next 12345 下5页 Last page